Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts– all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Asthma & COPD Therapies Market forecasts from 2019-2029
  • Profiles of the leading 20 asthma & COPD companies:
  • Aerocrine (Circassia)
  • ALK-Abello A/S
  • Amphastar Pharmaceuticals, Inc.
  • AstraZeneca
  • Boehringer Ingelheim
  • Chiesi Farmaceutici
  • Cipla
  • GlaxoSmithKline
  • Lallemand Pharma International
  • Merck
  • MundiPharma
  • Novartis
  • Pulmatrix
  • Roche
  • Sanofi/Regeneron
  • Sunovion
  • Teva
  • Theravance Biopharma|Mylan Inc.
  • Vectura Group plc
  • Verona Pharma plc
  • The content of each profile differs, depending on the organization. In general, a profile gives the following information:
  • An overview and analysis of the company
  • A portfolio of the company’s marketed product and product pipeline
  • Financial Information
  • Revenue forecast from 2019-2029
  • Recent developments
  • Future Outlook
  • This report discusses factors that drive and restrain the asthma and COPD market.
Visiongain’s study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


1 Report Overview
1.1 Global Asthma & COPD Companies Market Overview
1.2 Global Asthma & COPD Companies Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Key Questions Answered by this Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Introduction to Asthma & COPD Therapies
2.1 COPD Overview
2.1.1 Chronic Obstructive Pulmonary Disease Medications
2.2 Asthma Overview
2.2.1 Desirable inhaler characteristics for treating asthma
2.3 Asthma & COPD Respiratory Inhalers Overview
2.3.1 Nebulizers
2.3.2 Metered Dose Inhaler
2.3.3 Breath-Actuated Pressurised Metered-Dose Inhalers
2.3.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices
2.3.5 Dry powder inhalers (DPIs)
2.3.6 Soft Mist Inhalers
2.4 Asthma & COPD Therapies – Realising Their Potential, Market Drivers
2.4.1 Combination Therapies - Asthma & COPD Products
2.4.2 Triple Combination – Asthma & COPD Products
2.4.3 Opportunities in Telehealth
2.5 Market Restraints
2.6 Asthma & COPD Products: Trends and Developments
2.6.1 E-Technology in Asthma and COPD
3 Leading Asthma & COPD Companies: Overview, 2018
3.1 The Global Asthma & COPD Companies Market In 2018
3.2 Leading Companies in the Asthma & COPD Market, 2018
3.3 How Will Leading Companies’ Market Shares Change to 2029?
4 Leading Asthma & COPD Companies Worldwide, 2018
4.1 Astrazeneca – Company Overview & Analysis
4.1.1 AstraZeneca Marketed Asthma & COPD products
4.1.2 AstraZeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.1.3 AstraZeneca -Asthma & COPD Market Forecast, 2018-2029
4.2 GlaxoSmithKline – Company Overview & Analysis
4.2.1 GlaxoSmithKline Marketed Asthma & COPD products
4.2.2 GlaxoSmithKline, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.2.3 GlaxoSmithKline -Asthma & COPD Market Forecast, 2018-2029
4.3 Boehringer Ingelheim – Company Overview & Analysis
4.3.1 Boehringer Ingelheim Marketed Asthma & COPD products
4.3.2 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.3.3 Boehringer Ingelheim -Asthma & COPD Market Forecast, 2018-2029
4.4 Teva – Company Overview & Analysis
4.4.1 Teva Marketed Asthma & COPD products
4.4.2 Teva, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.4.3 Teva -Asthma & COPD Market Forecast, 2018-2029
4.5 Merck – Company Overview & Analysis
4.5.1 Merck Marketed Asthma & COPD products
4.5.2 Merck, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.5.3 Merck -Asthma & COPD Market Forecast, 2018-2029
4.6 Roche – Company Overview & Analysis
4.6.1 Roche Marketed Asthma & COPD products
4.6.2 Roche, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.6.3 Roche -Asthma & COPD Market Forecast, 2018-2029
4.7 Novartis – Company Overview & Analysis
4.7.1 Novartis Marketed Asthma & COPD products
4.7.2 Novartis, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.7.3 Novartis -Asthma & COPD Market Forecast, 2018-2029
4.8 Regeneron Pharmaceuticals (Sanofi)– Company Overview & ANALYSIS
4.8.1 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products- R&D Pipeline & Future Outlook
4.8.2 Regeneron Pharmaceuticals (Sanofi) -Asthma & COPD Market Forecast, 2018-2029
4.9 Mundipharma – Company Overview & Analysis
4.9.1 Mundipharma Marketed Asthma & COPD products
4.9.2 Mundipharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.10 Theravance Biopharma – Company Overview & Analysis
4.10.1 Theravance Biopharma Marketed Asthma & COPD products
4.10.2 Theravance Biopharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.11 Amphastar Pharmaceuticals – Company Overview & Analysis
4.11.1 Amphastar Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.12 Cipla– Company Overview & Analysis
4.12.1 Cipla Marketed Asthma & COPD products
4.13 Sunovion Pharmaceuticals– Company Overview & Analysis
4.13.1 Sunovion Pharmaceuticals: Marketed Asthma & COPD products
4.13.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.13.3 Sunovion -Asthma & COPD Market Forecast, 2018-2029
4.14 Aerocrine (Circassia)– Company Overview & Analysis
4.14.1 Circassia Marketed Asthma & COPD products
4.14.2 Circassia, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.14.3 Circassia -Asthma & COPD Market Forecast, 2018-2029
4.15 Vectura Group – Company Overview & Analysis
4.15.1 Vectura Group Marketed Asthma & COPD products
4.15.2 Vectura Group, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.15.3 Vectura Group -Asthma & COPD Market Forecast, 2018-2029
4.16 Lallemand Pharma Ag– Company Overview & Analysis
4.16.1 Lallemand Pharma AG Marketed Asthma & COPD products
4.16.2 Lallemand Pharma AG, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.16.3 Lallemand Pharma -Asthma & COPD Market Forecast, 2018-2029
4.17 Chiesi Farmaceutici S.P.A. – Company Overview & Analysis
4.17.1 Chiesi Farmaceutici S.p.A Marketed Asthma & COPD Products
4.17.2 Chiesi Farmaceutici, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.17.3 Chiesi Farmaceutici: -Asthma & COPD Market Forecast, 2018-2029
4.18 Pulmatrix: Company Overview & Analysis
4.18.1 Pulmatrix, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.19 Verona Pharma Plc– Company Overview & Analysis
4.19.1 Verona Pharma plc, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.19.2 Verona Pharma plc -Asthma & COPD Market Forecast, 2018-2029
4.20 Alk-Abelló A/S– Company Overview & Analysis
4.20.1 ALK-Abelló A/S Marketed Asthma & COPD Products
4.20.2 ALK-Abelló A/S, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.20.3 ALK-Abelló A/S -Asthma & COPD Market Forecast, 2018-2029
5 Conclusions
5.1 Asthma & COPD Products: A Maturing Market
5.2 The Global Asthma & COPD Companies Market In 2019
5.3 Leading Asthma & COPD Companies
5.4 Global Asthma & COPD Products Market Forecast 2019-2029
5.5 The Future of The Asthma & COPD Products Market
5.5.1 Growth in Anti-Inflammatory and Combination Drugs
5.5.2 Personalised Medicine
5.5.3 Unmet Needs in Asthma and COPD
5.6 Strategies for Growth in 2018-2029
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form
List of Tables
Table 2.1 Advantages and Disadvantages of the Main Types of Asthma Inhalers
Table 2.2 E-Technology Based Inhalers
Table 3.1 Global Market Forecast: Revenues ($bn), AGR (%) By Leading Companies, 2018-2029
Table 3.2 Leading Companies in Asthma & COPD diseases
Table 3.3 Leading Asthma & COPD Companies: Revenues ($bn) and Market Shares (%), 2019 And 2029
Table 4.1 Astrazeneca: Company Overview
Table 4.2 Astrazeneca: Products Portfolio
Table 4.3 Astrazeneca: Products Pipeline Portfolio
Table 4.4 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.5 Glaxosmithkline: Company Overview
Table 4.6 Glaxosmithkline: Products Portfolio
Table 4.7 Glaxosmithkline: Products Pipeline Portfolio
Table 4.8 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.9 Boehringer Ingelheim: Company Overview
Table 4.10 Boehringer Ingelheim: Products Portfolio
Table 4.11 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.12 Teva: Company Overview
Table 4.13 Teva: Products Portfolio
Table 4.14 Teva: Products Pipeline Portfolio
Table 4.15 Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.16 Merck: Company Overview
Table 4.17 Merck: Products Portfolio
Table 4.18 Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.19 Roche: Company Overview
Table 4.20 Roche: Products Portfolio
Table 4.21 Roche: Products Pipeline Portfolio
Table 4.22 Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.23 Novartis: Company Overview
Table 4.24 Novartis: Products Portfolio
Table 4.25 Novartis: Products Pipeline Portfolio
Table 4.26 Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.27 Regeneron Pharmaceuticals (Sanofi): Company Overview
Table 4.28 Regeneron Pharmaceuticals (Sanofi): Product Pipeline Portfolio
Table 4.29 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.30 Mundipharma: Company Overview
Table 4.31 Mundipharma: Products Portfolio
Table 4.32 Mundipharma: Products Pipeline Portfolio
Table 4.33 Theravance Biopharma: Company Overview
Table 4.34 Theravance Biopharma: Products Portfolio
Table 4.35 Theravance Biopharma: Products Pipeline Portfolio
Table 4.36 Amphastar Pharmaceuticals: Company Overview
Table 4.37 Amphastar Pharmaceuticals: Products Pipeline Portfolio
Table 4.38 Cipla: Company Overview
Table 4.39 Cipla: Products Portfolio
Table 4.40 Sunovion Pharmaceuticals: Company Overview
Table 4.41 Sunovion Pharmaceuticals: Products Portfolio
Table 4.42 Sunovion: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.43 Circassia: Company Overview
Table 4.44 Circassia: Products Portfolio
Table 4.45 Circassia: Products Pipeline Portfolio
Table 4.46 Vectura Group: Company Overview
Table 4.47 Vectura Group: Products Portfolio
Table 4.48 Vectura Group: Products Pipeline Portfolio
Table 4.49 Lallemand Pharma AG: Company Overview
Table 4.50 Lallemand Pharma AG: Products Portfolio
Table 4.51 Lallemand Pharma AG: Products Pipeline Portfolio
Table 4.52 Chiesi Farmaceutici S.P.A: Company Overview
Table 4.53 Chiesi Farmaceutici S.P.A: Products Portfolio
Table 4.54 Chiesi Farmaceutici S.P.A: Products Pipeline Portfolio
Table 4.55 Chiesi Farmaceutici S.P.A: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.56 Pulmatrix: Company Overview
Table 4.57 Pulmatrix: Products Pipeline Portfolio
Table 4.58 Verona Pharma Plc: Company Overview
Table 4.59 Verona Pharma Plc: Products Pipeline Portfolio
Table 4.60 Alk-Abelló A/S: Company Overview
Table 4.61 Alk-Abelló A/S Products Portfolio
Table 4.62 Alk-Abelló A/S: Products Pipeline Portfolio
List of Figures
Figure 1.1 Global Asthma & COPD Companies Market Segmentation Overview, 2019
Figure 2.1 Stepwise Approach to Treatment of COPD
Figure 2.2 Stepwise Approach to Treatment of Asthma
Figure 3.1 Global: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 3.2 Leading Asthma & COPD Drug Manufacturers: Revenue ($bn), 2019
Figure 3.3 Leading Asthma & COPD Drug Manufacturers: Market Share (%), 2019
Figure 3.4 Leading Asthma & COPD Companies: Revenues ($bn), 2029
Figure 3.5 Leading Asthma & COPD Companies: Market Shares (%), 2029
Figure 4.1 AstraZeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.2 GlaxoSmithKline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.3 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.4 Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.5 Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.6 Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.7 Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.8 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.9 Sunovion Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.10 Chiesi Farmaceutici Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 5.1 World Asthma & COPD Products Market Forecast: Revenues ($bn), 2019-2029

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook